HEMACARE STARTS CLINICALS ON AIDS TREATMENTHemaCare Corp. (NASDAQ: HEMA) of Sherman Oaks, Calif., saidthat it started clinical trials of its Passive HyperimmuneTherapy (PHT) for AIDS. Approved by California's Departmentof Health Services, the trials involve 225 ARC/AIDS patients.(For more information on PHT, keyword search IndustryLibrary for 062190PASSIVE, 060890HEMACARE,122189HEMACARE and 110289MEDICORP.)
ACTIVISTS APPLAUD END OF AIDS VICTIMS BAN
AIDS activists on Friday hailed Health and Human ServicesSecretary Louis Sullivan's proposal, expected to take effect nextJune, to drop human immunodeficiency virus (HIV) infection asa reason for barring the entry of foreign visitors to the UnitedStates. "It should have been done long ago," said Jim Driscoll ofAIDS Coalition to Unleash Power (ACT-UP).
DIAGNOSTIC PRODUCTS INCREASES DIVIDEND
Diagnostic Products Corp. (NYSE:DP) of Los Angeles raised itsquarterly cash dividend to 8 cents per share, a 33 percentincrease from its previous quarterly rate.
(c) 1997 American Health Consultants. All rights reserved.